Evidence map›Paper›PMID 39076279›Full record

ReviewReviews in cardiovascular medicine2023

Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?

Frederick Berro Rivera, Marianne Katharina Taliño, Marie Francesca Ansay, Gerard Francis Mangubat, Mer Lorraine Mahilum, Rajiv Hans Menghrajani, Siena Placino, Sung Whoy Cha, John Paul Aparece, Marc Gregory Yu and 4 more

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Frederick Berro RiveraDepartment of Medicine, Lincoln Medical and Mental Health Center, Bronx, NY 10451, USA.
Marianne Katharina TaliñoAteneo de Manila School of Medicine and Public Health, 1604 Pasig City, Philippines.
Marie Francesca AnsayAteneo de Manila School of Medicine and Public Health, 1604 Pasig City, Philippines.
Gerard Francis MangubatDepartment of Medicine, Southern Philippines Medical Center, 8000 Davao City, Philippines.
Mer Lorraine MahilumDepartment of Medicine, Southern Philippines Medical Center, 8000 Davao City, Philippines.
Rajiv Hans MenghrajaniSt. Luke's Medical Center College of Medicine - William H. Quasha Memorial, 1102 Manila, Philippines.
Siena PlacinoSt. Luke's Medical Center College of Medicine - William H. Quasha Memorial, 1102 Manila, Philippines.
Sung Whoy ChaCebu Institute of Medicine, 6000 Cebu City, Philippines.
John Paul ApareceCebu Institute of Medicine, 6000 Cebu City, Philippines.
Marc Gregory YuSection of Vascular Cell Biology, Joslin Diabetes Center and Harvard Medical School, Boston, MA 02215, USA.
Michael Lawrenz CoSection of Cardiology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Edgar LermaSection of Nephrology, University of Illinois at Chicago College of Medicine/Advocate Christ Medical Center, Oak Lawn, IL 60612, USA.
Krishnaswami VijayaraghavanUniversity of Arizona, Phoenix, AZ 85004, USA.
Peter A McCulloughTruth for Health Foundation, Tucson, AZ 85728, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with acromegaly carry a high risk of developing cardiovascular diseases (CVD). In fact, CVD is the leading cause of mortality among this group of patients. The most frequent cardiovascular complications are heart failure (HF), valvular disease, hypertension, arrhythmias, and coronary artery disease (CAD). The pathophysiology centers on the family of growth hormone (GH). These hormones are involved in normal cardiac development and function; however, excess of insulin-like growth factor-1 (IGF-1), the principally active hormone, can also cause negative effects on the cardiovascular system. HF in acromegaly usually presents with biventricular enlargement and diastolic dysfunction and is strongly associated with the duration of GH excess rather than the degree of hormone elevation. There is a high prevalence of valvular disease affecting aortic and mitral valves among patients with longer disease duration. The development of hypertension in acromegaly may be attributed to the effects of chronic GH/IGF-1 excess on different organ systems, which act via several mechanisms. The aspect of arrhythmia and CAD complicating acromegaly are currently not fully understood.

Indexed as

acromegalycardiovascular diseasesgrowth hormoneinsulin-like growth factor-1

Identifiers

PMID39076279
PMCPMC11273026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.